Uğur Şahin and Özlem Türeci, the couple and founders of BioNTech SE, plan to leave the company by the end of the year to establish a new biotechnology company focused on mRNA technology. Following the news, the company's American Depositary Receipts (ADR) plunged by as much as 21% in pre-market trading. Investors believe that the departure of the founders represents a significant blow to the company and its shareholders. Şahin stated that the company has entered a phase where speed and execution are paramount, and there are more suitable managers for the role. Currently, BioNTech boasts a market capitalization of $26 billion and is experiencing rapid growth. To support the new venture, BioNTech will inject certain rights and mRNA technology in exchange for equity stakes. This transition is the result of over 18 months of discussions, and amid U.S. political pressure on mRNA technology, the company has decided to increase its investment. The new company will be the third biotechnology firm established by the duo. BioNTech is currently bringing its first cancer therapy to market and diversifying its portfolio, while also seeking collaborations in China. The company expects its per-share loss to exceed expectations in 2025, with sales declining this year. However, it will continue to collaborate with the new company on potential joint therapies. The spin-off is expected to be completed by mid-2026.